Hereditary nonpolyposis colorectal cancer (HNPCC) is a common inherited form of neoplasia caused by germline mutations in DNA mismatch repair (MMR) genes. MMR proteins have been reported to associate with several proteins, including the human exonuclease 1 (hEXO1). We report here novel HNPCC ± hMLH1 mutant proteins (T117M, Q426X and 1813insA) in Danish HNPCC patients. We demonstrate that these mutant HNPCC ± hMLH1 proteins are unable to form complexes with hEXO1 and hPMS2 in vivo. The results indicate that mutations found in HNPCC gene carriers disrupt hMLH1 ± hEXO1 complex formation and hMutLa heterodimer assembly essential for MMR activity. Keywords: hEXO1; hMLH1; hPMS2; DNA mismatch repair; HNPCC Hereditary nonpolyposis colorectal cancer (HNPCC) is a genetically heterogeneous disorder caused by germline mutations in one of several MMR genes (Jiricny, 1998a,b) , although current evidence suggests that germ-line mutations in hMSH2 and hMLH1 account for the majority of HNPCC cases (PeltomaÈ ki and Vasen, 1997) . HNPCC gene carriers inherit a mutation in one of the alleles encoding a MMR gene, and the second copy is mutated or lost as an early event in the development of a tumor. This second event renders cells DNA mismatch repair (MMR) de®cient, presumably leading to the rapid accumulation of mutations that drives tumor development. What exactly causes the underlying predisposition to colorectal cancer in HNPCC individuals remains to be elucidated. It has been shown that an accurate assembly of human MMR complexes is essential for ecient MMR in order to maintain the genomic integrity (Drummond et al., 1997) . These data suggest that, depending on the nature of the mutation in the MMR genes, and the expression of these, the composition, and with that the activity, of the DNA repair complexes varies among HNPCC individuals. Also, the involvement of at least hMLH1 and hMSH2 in other cellular pathways, such as DNA recombination and cell cycle checkpoint regulation (Jiricny, 1998a,b) , that control the stability of the genome may be aected by mutations in the hMLH1 and hMSH2 genes. Therefore, tumor development and disease course may vary among HNPCC families (JaÈ ger et al., 1997). The signi®cance of protein ± protein interactions in the repair complexes is supported by the ®ndings that hMSH2 exists in complex with either hMSH6 (hMutSa) or hMSH3 (hMutSb) and the hMLH1 protein in complex with either hPMS2 (hMutLa), hPMS1 (hMutLb) or hMLH3 (Drummond et al., 1995; Li and Modrich, 1995; Lipkin et al., 2000; Papadopoulos et al., 1995; RaÈ schle et al., 1999) . The hMSH2 protein has also been shown to interact with human exonuclease 1 (hEXO1) (Rasmussen et al., 2000; Schmutte et al., 1998) . While, it is not known whether hEXO1 is involved in MMR, yeast strains de®cient in exonuclease 1 activity show increased spontaneous mutation rates and a small increase in recombination when the heteroduplex intermediate contains base ± base mismatches or small loops (Nicholson et al., 2000; Tischko et al., 1997 Tischko et al., , 1998 . It is known that both exonuclease 1 (EXO1) and MMR proteins are involved in homologous recombination (Fiorentini et al., 1997; Saparbaev et al., 1996; Sugawara et al., 1997) and that yeast EXO1 plays a role in double-stranded break repair and meiotic crossing over (Tsubouchi and Ogawa, 2000) .
Many studies of HNPCC have focused on identi®ca-tion of mutations in the hMLH1 and hMSH2 genes. However, mutational analysis of these genes does not determine the molecular and biochemical defects underlying this disease. To improve understanding of the relationship between loss of hMLH1 gene function and HNPCC, we characterized speci®c protein ± protein interactions of the hMutLa and hMLH1 ± hEXO1 complexes, using mutant forms of hMLH1 found in HNPCC patients. We employed the yeast two-hybrid system as well as a glutathione S-transferase (GST)-fusion interaction (pull-down) assay to study such protein ± protein interactions in vivo and in vitro, respectively.
The hMLH1 protein exists predominately in a complex with hPMS2 also known as the hMutLa heterodimer . The formation of a hMutLa complex is essential for MMR activity (Baker et al., 1995 (Baker et al., , 1996 Edelmann et al., 1996) and thus the inability of HNPCC-hMLH1 proteins to form a complex with hPMS2 could result in inecient MMR activity in HNPCC individuals. To investigate the potential cause underlying HNPCC we examined whether three hMLH1 mutants identi®ed in Danish HNPCC patients ( Figure 1 ) were able to interact with hPMS2. The mutations included a threonine to methionine missense mutation at codon 117 (T117M) of hMLH1 and two novel HNPCC mutations, a nonsense mutation (CAG to TAG) at codon 426 (Q426X) and a frame-shift mutation (insertion of A at nucleotide 1813) resulting in a premature stop at codon 609 (1813insA) (Figure 1 ). The pull-down assay with recombinant GST-tagged HNPCC proteins and in vitro transcribed and translated (IVTT) hPMS2 revealed as expected the formation of a complex between hMLH1 and hPMS2 ( Figure 2a , lanes 5 and 10). Furthermore, we detected the formation of a complex between HNPCC ± hMLH1 (T117M) and hPMS2 ( Figure 2a , lane 11). Although, we found that the HNPCC ± hMLH1 (T117M) protein is expressed in eukaryotic NIH3T3 cells (data not shown) we were unable to reproduce the interaction with hPMS2 in the yeast twohybrid assay (Figure 3a) . One explanation for this discrepancy could be the threefold reduced complex formation between hPMS2 and the HNPCC ± hMLH1 (T117M) mutant protein compared to the hPMS2 and hMLH1 proteins as quantitated with a phosphoimager (data not shown) ( Figure 2a , lanes 10 and 11). In contrast, complex formations between the hMLH1 protein truncations, HNPCC ± hMLH1 (Q426X) and HNPCC ± hMLH1 (1813insA), and hPMS2 were not detected in any of the assays (Figure 2a , lanes 12 and 13 and Figure 3a) . A faint band in the pull-down reaction containing HNPCC ± hMLH1 (1813insA) and hPMS2 was visible (Figure 2a , lane 13) but the intensity was similar to the band obtained in the reaction containing only hPMS2 protein (Figure 2a , lane 3) and it is, therefore, unlikely that it represents a true complex between HNPCC ± hMLH1 (1813insA) and hPMS2.
Consistently, it has previously been shown by deletion mutagenesis that hMLH1 and hPMS2 interaction is mediated through the C-terminal part of hMLH1 (amino acids 506 ± 756) and the C-terminal part of hPMS2 (amino acids 675 ± 850) (Figure 1b ) (Guerrette et al., 1999) . The HNPCC ± hMLH1 (T117M) mutation has been reported in nine unrelated HNPCC families from dierent parts of the world (www.nfdht.nl/database/mlh1-4.htm and data not shown) suggesting as already demonstrated in yeast (Shcherbakova and Kunkel, 1999; Shimodaira et al., 1998) , that the mutation is not a linked polymorphism. The HNPCC ± hMLH1 (T117M) mutation maps to a conserved sequence (Figure 1) , which is believed to be directly involved in binding and/or hydrolysis of ATP (Ban et al., 1999) . Thus, the HNPCC ± hMLH1 (T117M) missense mutation may inactivate MMR activity by altering the capacity of this mutant protein to bind and/or hydrolyze ATP and with that complex formation with other MMR proteins. In agreement with this hypothesis we show that HNPCC individuals carrying the HNPCC ± hMLH1 (T117M), HNPCC ± hMLH1 (Q426X) and HNPCC ± hMLH1 (1813insA) mutations are impaired in hMutLa heterodimer formation, which leads to a defect in MMR activity when the second hMLH1 allele is lost or inactivated.
In an attempt to identify tissue-speci®c MMRassociated factors, we and others have recently identi®ed a human exonuclease that interacts with hMSH2 (Rasmussen et al., 2000; Schmutte et al., 1998; Tishko et al., 1998; Wilson III et al., 1998) . We demonstrated that hMSH2 interacts with both forms of hEXO1, hEXO1b and hEXO1a/HEX1, and that this interaction is mediated through their C-terminal domains. In contrast, we did not detect any interaction between hMSH6 and hEXO1 in the two-hybrid system (Rasmussen et al., 2000) . It is not known whether hEXO1 plays a role in MMR or whether its interaction with hMSH2 is important for recombination. We show that the hMLH1 protein, like hMSH2, interacts with both forms of hEXO1 (hEXO1b and hEXO1a/HEX1) and that this interaction is mediated through the Cterminal domains of the exonucleases (Figure 2b , lanes 5 and 8 and Figure 3) . We did not detect any interaction between hPMS2 and hEXO1 ( Figure  3a ,c). Our preliminary data suggest that the presence of both hMLH1 and hPMS2 proteins did not prevent hEXO1 from binding to hMLH1 (data not shown). Therefore, we do not think that hMutLa formation necessarily block hEXO1 binding to hMLH1. To further characterize the hMLH1 ± hEXO1 interaction we constructed¯uorescent protein fusions of both hMLH1 and hEXO1 and introduced them in NIH3T3 cells (Figure 4) . Our results reveal that CFP ± hMLH1 is primarily present in the nucleus but we also detect a fraction of this protein in the cytoplasm (Figure 4 , panel 1). In contrast, we only detect YFP ± hEXO1 in the nucleus (Figure 4, panel 2 ). Upon cotransfection with YFP ± hEXO1, however, CFP ± hMLH1 was entirely nuclear (Figure 4, panels 3 and 4) .
In summary, these results demonstrate that at least two MMR proteins namely, hMSH2 and hMLH1, interact with human exonuclease 1 while two other MMR proteins, hPMS2 and hMSH6, are not directly involved in hEXO1 interaction when assessed in the in vivo two-hybrid assay.
To examine whether hMLH1 and hEXO1 interactions might be aected in HNPCC patients, the association of the three hMLH1 mutant proteins described above with hEXO1 was characerized. Positive interaction was only demonstrated between HNPCC ± hMLH1 (T117M) and the full-length hEXO1b protein via the in vitro pull-down assay (Figure 2b, lane 9) . However, using the in vivo two-hybrid assay protein ± protein interactions between the HNPCC ± hMLH1 proteins and the tested exonuclease 1 constructs could Figure 1 (a) Sequence alignment of the MutL family. hMLH1: human MutL homolog hMLH1, yMLH1: Saccharomyces cerevisiae MutL homolog MLH1, MutL: Escherichia coli MutL. Conserved residues are shown in bold type. Sequence alignment was performed using ClustalW Multiple Sequence Alignment. (b) Structures of the hPMS2, hMLH1, HNPCC ± hMLH1 (T117M), HNPCC ± hMLH1 (Q426X), HNPCC ± hMLH1 (1813insA), hEXO1a/HEX1, hEXO1b, hEXO1a/HEX1-N-terminal, hEXO1a/ HEX1-C-terminal and hEXO1b-C-terminal (Y5) proteins. Three Danish families diagnosed with HNPCC were identi®ed through the Danish HNPCC register. Two novel HNPCC mutations, a nonsense mutation (CAG to TAG) at codon 426 (Q426X) and a frame-shift mutation (insertion of A at nucleotide 1813) resulting in a premature stop at codon 609 (1813insA) of hMLH1, were identi®ed in families which ful®lled the Amsterdam criteria. The third mutation, a threonine to methionine missense mutation at codon 117 (T117M) of hMLH1 has previously been described (www.nfdht.nl/database/mlh1-4.htm). The hMLH1 coding region was cloned into the EcoRI site of pcDNA3 and used as template for primer-mediated mutagenesis to construct the three dierent HNPCC mutations in hMLH1, T117M, Q426X, and 1813insA. The DNA sequence of all synthetic mutations and PCR-ampli®ed fragments were con®rmed by DNA sequencing. The other constructs used in this study are hPMS2 (full-length cDNA), HEX1-N (1355 bp N-terminal region of HEX1/hEXO1a), HEX1-C (1182 bp C-terminal region of HEX1/hEXO1a), and hEXO1b-C (Y5) (1952 bp C-terminal region of hEXO1b). All the hEXO1 constructs are described in detail in Rasmussen et al., 2000) not be detected (Figure 3 ). We were unable to study the interaction between full-length hEXO1 fused to the GAL4 activation domain and the hMLH1 proteins since these constructs are non-functional in the yeast Figure 2 GST fusion protein assay to study the interaction between hMLH1 proteins and hEXO1b or hPMS2. (a) Lane 1, Labeled IVTT hPMS2 protein; lane 2,+GST beads; lane 3,+BL21 lysate; lane 4,+puri®ed GST protein; lane 5,+puri®ed GST ± hMLH1 protein; lane 6, puri®ed GST ± hMLH1 protein and labeled IVTT vector; lane 7, puri®ed GST ± HNPCC ± hMLH1 (T117M) protein and labeled IVTT vector; lane 8, puri®ed GST ± HNPCC ± hMLH1 (Q426X) protein and labeled IVTT vector; lane 9, puri®ed GST ± HNPCC ± hMLH1 (1813insA) protein and labeled IVTT vector; lane 10, puri®ed GST ± hMLH1 protein and labeled IVTT hPMS2 protein; lane 11, puri®ed GST ± HNPCC ± hMLH1 (T117M) protein and labeled IVTT hPMS2 protein; lane 12, puri®ed GST ± HNPCC ± hMLH1 (Q426X) protein and labeled IVTT hPMS2 protein; and lane 13, puri®ed GST ± HNPCC ± hMLH1 (1813insA) protein and labeled IVTT hPMS2 protein. (b) Lane 1, IVTT hEXO1b protein; lane 2,+GST beads; lane 3,+BL21 lysate; lane 4,+puri®ed GST protein; lane 5,+puri®ed GST ± hMLH1 protein; lane 6, puri®ed GST ± hMLH1 protein and labeled IVTT vector; lane 7, puri®ed GST ± hMSH2 protein and labeled IVTT hEXO1b protein; lane 8, puri®ed GST ± hMLH1 protein and labeled IVTT hEXO1b protein; lane 9, puri®ed GST ± HNPCC ± hMLH1 (T117M) protein and labeled IVTT hEXO1b protein; lane 10, puri®ed GST ± HNPCC ± hMLH1 (Q426X) protein and labeled IVTT hEXO1b protein; and lane 11, puri®ed GST ± HNPCC ± hMLH1 (1813insA) protein and labeled IVTT hEXO1b protein. All in vitro transcription translation reactions were carried out using the TNT coupled reticulocyte lysate system (Promega). Brie¯y, lysates were incubated with 1 mg of DNA, amino acid mix lacking cysteine,
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S-Cysteine and T9 RNA polymerase, for 90 min at 308C, according to manufacturers instructions. The pGEX vector (Pharmacia-Amersham) was used to construct GST ± hMLH1, GST ± hMLH1 (T117M), GST ± hMLH1 (Q426X), GST ± hMLH1 (1813insA), and GST ± hMSH2. All the pGEX constructs are Nterminal GST-fusion proteins. DNA sequencing of the complete coding region con®rmed all constructs. The fusion proteins were puri®ed as described by Guerrette et al. (1998) , except for using non-induced E. coli cultures. The pull-down assays were performed as described by Guerrette et al. (1998) , except for incubating the proteins for 2 h at 308C before the reaction mixtures were loaded on the gels Figure 3 Interaction of hMLH1, HNPCC ± hMLH1 (T117M), HNPCC ± hMLH1 (Q426X), and HNPCC ± hMLH1 (1813insA) with hPMS2 or hEXO1 in the yeast two-hybrid system. (a) The bgalactosidase activity, listed as Miller units, was determined as described in Rasmussen et al. (2000) . (b) and (c) Strains containing various plasmids were streaked on SD-LEU-TRP+X-gal plates. The plasmids contained in each strain tested are indicated at the top of each column and at the left of each row. AD: activation domain, BD: binding domain. The yeast twohybrid vectors pAS2-1, pBRIDGE, and pACT2 (CLONTECH) were used to construct GAL4 fusion proteins. The yeast twohybrid assays were performed as previously described (Rasmussen et al., 2000) . Brie¯y, the coding regions of hMLH1 or HNPCC ± hMLH1 were ampli®ed by PCR and cloned into the EcoRI and BamHI sites of pBRIDGE or the NcoI and BamHI sites of pACT2. hPMS2 was ampli®ed by PCR using pREP4 ± hPMS2 (Risinger et al., 1998) as template and cloned into the NdeI and BamHI site of pAS2-1 and the SmaI and EcoRI sites of pACT2. All other plasmids are described in Rasmussen et al. (2000) . None of the plasmids showed any interaction with the two-hybrid vectors without insert two-hybrid assay (Rasmussen et al., 2000) . Similarly, we found that the hMLH1 and the hMLH1 derivatives fused to the GAL4 activation domain resulted in fusion proteins that are non-functional in the two-hybrid assay (Figure 3 and data not shown).
In conclusion, our results reveal that three novel HNPCC ± hMLH1 mutations known to cosegregate with suceptibility to cancer in HNPCC patients lead to a defect in assembly of the hMutLa heterodimer that could result in reduced MMR activity. Similarly, the HNPCC ± hMLH1 mutant proteins are also unable to interact with the newly identi®ed hEXO1 protein, a protein that now appears to interact with hMLH1 and hMSH2, but not hMSH6 and hPMS2. Presently, the precise biological pathways and overall contributions of these documented interactions remain unclear, largely because hMLH1 has been found to play a role in both MMR and recombination. Dissecting the molecular defects in HNPCC by testing of pathogenic MMR proteins in functional assays designed to quantitate interactions in the protein complexes should, together with mutational screening, immunohistochemistry and microsatellite analysis, help in developing strategies to diagnose and treat HNPCC carriers. Figure 4 Nuclear localization of CFP ± hMLH1 and YFP ± hEXO1b fusion proteins. On the day of treatment murine NIH3T3 cells were transiently transfected with 3.5 mg CFP ± hMLH1 (panel 1) or of YFP ± hEXO1b (panel 2) or both constructs (panels 3 and 4). Cells were incubated overnight and the next day the subcellular localization of the fusion proteins was examined by confocal laser scanning microscopy. The transfected cells are moreover shown in the corresponding Nomarski picture. The hMLH1 cDNA was cloned into the EcoRI and BamHI sites of the pECFP-C2 vector (CLONTECH) and hEXO1b cDNA was cloned into the BamHI and SalI sites of the pEYFP-C1 vector (CLONTECH 
